Techbase Medical Defense (ATD)
Abstract
Project TM3 supports preclinical and early phase clinical development of vaccines, therapeutic drugs, and diagnostic capabilities to provide safe and effective medical defense against validated biological threat agents or emerging infectious disease biothreats including bacteria, toxins, and viruses. After FY 2022, the Chemical Biological Defense Program (CBDP) RDT&E Projects were restructured to align with the CBDP portfolio construct. TM3 efforts in FY 2022 progress to Projects EN3, MT3, PT3, and UN3. This restructuring provides standardization and alignment across CBDP research, development and acquisition efforts. Individual efforts in this project include: - Innovative biotechnology approaches to advance medical systems designed to rapidly identify, diagnose, prevent, and treat disease due to exposure to biological threat agents will be evaluated. - Rapid development of medical countermeasure solutions is a crucial modernization strategy to avoid technological surprise against an expanding and sophisticated biological weapons of mass destruction (WMD) threat. Techbase Medical Defense (ATD), therefore, supports the Discovery of Medical Countermeasures Against New and Emerging (DOMANE) threat thrust, which is designed to develop technologies that support understanding, mitigating, and protecting against new and emerging biological threats to include viral, bacterial, and biotoxins. - Supports the advanced development of medical countermeasures to include prophylaxes, pretreatments, antidotes and therapeutic drugs against new and emerging biological threats. Demonstration of safety and toxicity data through adaptive trials for repurposed U.S. Food & Drug Administration (FDA) approved drugs, novel broad-spectrum drugs and drug combinations supporting submitting Investigational New Drug (IND) processes or Emergency Use Authorizations (EUA). Additionally, this effort supports development of technologies that protect, mitigate and understand new and emerging threats by forecasting pathogenesis and toxicity, structural determinations utilizing high throughput systems to identify both host and pathogen targets using advanced Artificial Intelligence (AI) and a curated repository of high-resolution 3D macromolecular structures to generate drug candidates. - Leverage lessons learned to shorten future emergency response timelines, mitigate impacts of biological threat outbreaks, and create interim capabilities to protect the warfighter. Leveraging interagency, industry, and academia partnership to build the warfighter's bio-armor to protect against biological threat families. Develop alternative vaccine platform technologies and manage awards utilizing go/no-go checkpoints along the development pathway.
Document Details
- Document Type
- Project
- Publication Date
- Oct 01, 2024
- Source ID
- TM3_0603384BP_3_0400_PB_2024
Related Documents
- Root: Chemical and Biological Defense Program - Advanced Development
- Child Accomplishment: 1) Battlefield Readiness - Chemical and Biological Incidence Preparedness and Response (CBIPR)
- Child Accomplishment: 2) Diagnostic Building Blocks - Chemical and Biological Incidence Preparedness and Response (CBIPR)
- Child Accomplishment: 3) Emerging Threats - Chemical and Biological Incidence Preparedness and Response (CBIPR)
- Child Accomplishment: 4) Medical Countermeasures Initiative
- Child Accomplishment: 5) Medical Countermeasures Initiative - Validated Nucleic Acid Vaccine Construction
- Child Accomplishment: 6) Battlefield Readiness
- Child Accomplishment: 7) Chemical Diagnostics
- Child Accomplishment: 8) Clinical Evaluation
- Child Accomplishment: 9) Diagnostic Building Blocks
- Child Accomplishment: 10) Emerging Threats
- Child Accomplishment: 11) Bacterial/Viral/Toxin/Broad Spectrum Prophylaxis
- Child Accomplishment: 12) Internal COVID - VSV SARS CoV-2 vaccine
- Child Accomplishment: 13) Bacterial Therapeutics
- Child Accomplishment: 14) Toxin Therapeutics
- Child Accomplishment: 15) Viral Therapeutics
- Child Accomplishment: 16) Nerve Agent Prophylaxis/Pretreatments
- Child Accomplishment: 17) Pharmaceutical Based Agents (PBAs)
- Child Accomplishment: 18) Reactivators of AChE as Therapeutics (ReACT)